Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

被引：0
作者：
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
机构：
[1] St. Josef-Hospital/Ruhr-University Bochum,Medical Image Analysis Center
[2] University Hospital Basel,Barts and The London School of Medicine and Dentistry
[3] Queen Mary University of London,Department of Neurology
[4] University of Warmia and Mazury,Department of Neurology, First Faculty of Medicine
[5] Charles University,undefined
[6] Hospital Vall d’Hebron University,undefined
[7] Rush University Medical Center,undefined
[8] DKD Helios Klinik Wiesbaden,undefined
[9] AbbVie Inc.,undefined
[10] Biogen,undefined
[11] Biogen,undefined
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Daclizumab beta; Relapsing–remitting multiple sclerosis; SELECTED; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2851 / 2864
页数：13
相关论文
共 50 条
  • [41] A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
    van Rhee, Frits
    Casper, Corey
    Voorhees, Peter M.
    Fayad, Luis E.
    de Velde, Helgi van
    Vermeulen, Jessica
    Qin, Xiang
    Qi, Ming
    Tromp, Brenda
    Kurzrock, Razelle
    ONCOTARGET, 2015, 6 (30) : 30408 - 30419
  • [42] Bimekizumab efficacy and safety in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from BE COMPLETE and its open-label extension to 1 year
    Coates, L.
    Landewe, R.
    Mclnnes, I.
    Mease, P.
    Ritchlin, C.
    Tanaka, Y.
    Asahina, A.
    Behrene, F.
    Gladman, D.
    Gossecic, L.
    Gottlieb, A.
    Warren, R.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Neregard, P.
    Merola, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 81 - 83
  • [43] Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States
    Berman, Gary
    Thiry, Alexandra
    Croop, Robert
    JOURNAL OF PAIN RESEARCH, 2024, 17 : 1805 - 1814
  • [44] Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study
    Manes, Marta
    Alberici, Antonella
    Di Gregorio, Eleonora
    Boccone, Loredana
    Premi, Enrico
    Mitro, Nico
    Pasolini, Maria Pia
    Pani, Claudia
    Paghera, Barbara
    Orsi, Laura
    Costanzi, Chiara
    Ferrero, Marta
    Tempia, Filippo
    Caruso, Donatella
    Padovani, Alessando
    Brusco, Alfredo
    Borroni, Barbara
    PARKINSONISM & RELATED DISORDERS, 2019, 63 : 191 - 194
  • [45] Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years
    Lublin, Fred D.
    Cofield, Stacey S.
    Cutter, Gary R.
    Gustafson, Tarah
    Krieger, Stephen
    Narayana, Ponnada A.
    Nelson, Flavia
    Salter, Amber R.
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 95 - 102
  • [46] BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study
    Ljung, Rolf
    Chan, Anthony K. C.
    Ahuja, Sanjay P.
    Mancuso, Maria Elisa
    Marquez, Jose Francisco Cabre
    Volk, Florian
    Blanchette, Victor
    Kerlin, Bryce A.
    Trakymiene, Sonata Saulyte
    Glosli, Heidi
    Kenet, Gili
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (03) : 556 - 565
  • [47] Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal A.
    Zhang, Meng
    Ozturk, Zafer E.
    Shumel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1608 - 1616
  • [48] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Puig, Luis
    Lebwohl, Mark
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Gomez, Natalie Nunez
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
  • [49] Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (10) : 1580 - 1584
  • [50] Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study
    Lesley M. Arnold
    Kenneth N. Schikler
    Lucinda Bateman
    Tahira Khan
    Lynne Pauer
    Pritha Bhadra-Brown
    Andrew Clair
    Marci L. Chew
    Joseph Scavone
    Pediatric Rheumatology, 14
12345